These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. Gao S; Chen S; Han D; Wang Z; Li M; Han W; Besschetnova A; Liu M; Zhou F; Barrett D; Luong MP; Owiredu J; Liang Y; Ahmed M; Petricca J; Patalano S; Macoska JA; Corey E; Chen S; Balk SP; He HH; Cai C Nat Genet; 2020 Oct; 52(10):1011-1017. PubMed ID: 32868907 [TBL] [Abstract][Full Text] [Related]
3. Pioneer of prostate cancer: past, present and the future of FOXA1. Teng M; Zhou S; Cai C; Lupien M; He HH Protein Cell; 2021 Jan; 12(1):29-38. PubMed ID: 32946061 [TBL] [Abstract][Full Text] [Related]
4. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Wang Z; Petricca J; Liu M; Zhang S; Chen S; Li M; Besschetnova A; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Vedadi M; Arrowsmith CH; He HH; Cai C Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2220472120. PubMed ID: 37549269 [TBL] [Abstract][Full Text] [Related]
5. FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer. Wang Z; Townley SL; Zhang S; Liu M; Li M; Labaf M; Patalano S; Venkataramani K; Siegfried KR; Macoska JA; Han D; Gao S; Risbridger GP; Taylor RA; Lawrence MG; He HH; Selth LA; Cai C Nat Commun; 2024 Jun; 15(1):4914. PubMed ID: 38851846 [TBL] [Abstract][Full Text] [Related]
6. Unveiling the Molecular Landscape of Hwang KW; Yun JW; Kim HS Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958805 [TBL] [Abstract][Full Text] [Related]
7. Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Parolia A; Cieslik M; Chu SC; Xiao L; Ouchi T; Zhang Y; Wang X; Vats P; Cao X; Pitchiaya S; Su F; Wang R; Feng FY; Wu YM; Lonigro RJ; Robinson DR; Chinnaiyan AM Nature; 2019 Jul; 571(7765):413-418. PubMed ID: 31243372 [TBL] [Abstract][Full Text] [Related]
8. A rare variant, which destroys a FoxA1 site at 8q24, is associated with prostate cancer risk. Hazelett DJ; Coetzee SG; Coetzee GA Cell Cycle; 2013 Jan; 12(2):379-80. PubMed ID: 23255135 [No Abstract] [Full Text] [Related]
9. Forkhead domain mutations in FOXA1 drive prostate cancer progression. Gao S; Chen S; Han D; Barrett D; Han W; Ahmed M; Patalano S; Macoska JA; He HH; Cai C Cell Res; 2019 Sep; 29(9):770-772. PubMed ID: 31324883 [No Abstract] [Full Text] [Related]
10. FOXA1 regulates alternative splicing in prostate cancer. Del Giudice M; Foster JG; Peirone S; Rissone A; Caizzi L; Gaudino F; Parlato C; Anselmi F; Arkell R; Guarrera S; Oliviero S; Basso G; Rajan P; Cereda M Cell Rep; 2022 Sep; 40(13):111404. PubMed ID: 36170835 [TBL] [Abstract][Full Text] [Related]
11. FOXA1: a transcription factor with parallel functions in development and cancer. Bernardo GM; Keri RA Biosci Rep; 2012 Apr; 32(2):113-30. PubMed ID: 22115363 [TBL] [Abstract][Full Text] [Related]
12. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation. He Y; Zhao Y; Wang L; Bohrer LR; Pan Y; Wang L; Huang H Oncogene; 2018 Jan; 37(4):534-543. PubMed ID: 28991226 [TBL] [Abstract][Full Text] [Related]
13. The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer. Kashyap V; Ahmad S; Nilsson EM; Helczynski L; Kenna S; Persson JL; Gudas LJ; Mongan NP Mol Oncol; 2013 Jun; 7(3):555-66. PubMed ID: 23384557 [TBL] [Abstract][Full Text] [Related]
14. LSD1 dual function in mediating epigenetic corruption of the vitamin D signaling in prostate cancer. Battaglia S; Karasik E; Gillard B; Williams J; Winchester T; Moser MT; Smiraglia DJ; Foster BA Clin Epigenetics; 2017; 9():82. PubMed ID: 28811844 [TBL] [Abstract][Full Text] [Related]
15. Genetic alterations and changes in expression of histone demethylases in prostate cancer. Suikki HE; Kujala PM; Tammela TL; van Weerden WM; Vessella RL; Visakorpi T Prostate; 2010 Jun; 70(8):889-98. PubMed ID: 20127736 [TBL] [Abstract][Full Text] [Related]
16. Genetic features of TP53 mutation and its downstream FOXA1 in prostate cancer. Xu X; Xie L; Meng L; Geng S; Liu J; Cao X; Dong Z; Xing Z Biosci Trends; 2022 Jul; 16(3):221-229. PubMed ID: 35768267 [TBL] [Abstract][Full Text] [Related]
17. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Liang Y; Ahmed M; Guo H; Soares F; Hua JT; Gao S; Lu C; Poon C; Han W; Langstein J; Ekram MB; Li B; Davicioni E; Takhar M; Erho N; Karnes RJ; Chadwick D; van der Kwast T; Boutros PC; Arrowsmith CH; Feng FY; Joshua AM; Zoubeidi A; Cai C; He HH Cancer Res; 2017 Oct; 77(20):5479-5490. PubMed ID: 28916652 [TBL] [Abstract][Full Text] [Related]
18. Androgen receptor-independent function of FoxA1 in prostate cancer metastasis. Jin HJ; Zhao JC; Ogden I; Bergan RC; Yu J Cancer Res; 2013 Jun; 73(12):3725-36. PubMed ID: 23539448 [TBL] [Abstract][Full Text] [Related]
19. FOXA1 promotes prostate cancer angiogenesis by inducing multiple pro-angiogenic factors expression. Su Y; Zhang Y; Zhao J; Zhou W; Wang W; Han B; Wang X J Cancer Res Clin Oncol; 2021 Nov; 147(11):3225-3243. PubMed ID: 34258652 [TBL] [Abstract][Full Text] [Related]
20. Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program. Jin HJ; Zhao JC; Wu L; Kim J; Yu J Nat Commun; 2014 May; 5():3972. PubMed ID: 24875621 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]